Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

INTRODUCTION: Ertugliflozin is a sodium-glucose cotransporter 2 inhibitor in development for type 2 diabetes mellitus (T2DM). The safety and efficacy of ertugliflozin were evaluated over 52 weeks in patients with chronic kidney disease (CKD). METHODS: In this double-blind randomized study (NCT019868...

Descripción completa

Detalles Bibliográficos
Autores principales: Grunberger, George, Camp, Sarah, Johnson, Jeremy, Huyck, Susan, Terra, Steven G., Mancuso, James P., Jiang, Zhi Wei, Golm, Gregory, Engel, Samuel S., Lauring, Brett
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801223/
https://www.ncbi.nlm.nih.gov/pubmed/29159457
http://dx.doi.org/10.1007/s13300-017-0337-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801223/
https://www.ncbi.nlm.nih.gov/pubmed/29159457
http://dx.doi.org/10.1007/s13300-017-0337-5

Ejemplares similares